Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory and Malignant Disease: Translating TNF-α Experience to Oncology

被引：67

作者：

Munnink, T. H. Oude ^{[1
]}

Henstra, M. J.

Segerink, L. I. ^{[2
,3
]}

Movig, K. L. L. ^{[1
]}

Brummelhuis-Visser, P.

机构：

[1] Med Spectrum Twente, Dept Clin Pharm, Enschede, Netherlands

[2] Univ Twente, MESA Inst Nanotechnol, BIOS Lab Chip Grp, POB 217, ZL-7500 AE Enschede, Netherlands

[3] Univ Twente, MIRA Inst Biomed Engn & Tech Med, POB 217, NL-7500 AE Enschede, Netherlands

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷 / 04期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; METASTATIC BREAST-CANCER; PROGRESSION-FREE SURVIVAL; INFLIXIMAB TROUGH LEVELS; B-CELL LYMPHOMA; RHEUMATOID-ARTHRITIS; BOWEL-DISEASE; POPULATION PHARMACOKINETICS; CROHNS-DISEASE; COLORECTAL-CANCER;

D O I：

10.1002/cpt.211

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lack of response to monoclonal antibodies (mAbs) has been associated with inadequate mAb serum concentrations. Therapeutic drug monitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability of mAb pharmacokinetics, summarizes exposure-response data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementing mAb-TDM.

引用

页码：419 / 431

页数：13

共 50 条

[1] Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease
Baert, Filip
DIGESTIVE DISEASES, 2015, 33 : 70 - 77
[2] Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Papamichael, Konstantinos
Cheifetz, Adam S.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (12) : 1423 - 1431
[3] The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease
Sheasgreen C.
Nguyen G.C.
Current Gastroenterology Reports, 2017, 19 (5)
[4] Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
Di Paolo, Antonello
Luci, Giacomo
FRONTIERS IN PHARMACOLOGY, 2021, 11
[5] The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases
Mingas, Panagiotis-Dimitrios
Zdovc, Jurij
Grabnar, Iztok
Vovk, Tomaz
MOLECULES, 2021, 26 (06):
[6] Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease
Roblin, Xavier
Riviere, Pauline
Flamant, Mathurin
Veyrard, Pauline
Poullenot, Fabien
Paul, S.
Laharie, David
INFLAMMATORY BOWEL DISEASES, 2018, 24 (09) : 1904 - 1909
[7] Therapeutic drug monitoring in inflammatory bowel disease
Jossen, Jacqueline
Dubinsky, Marla
CURRENT OPINION IN PEDIATRICS, 2016, 28 (05) : 620 - 625
[8] Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties
Imamura, Chiyo K.
DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : 14 - 18
[9] Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease
Frank I. Scott
Gary R. Lichtenstein
Current Treatment Options in Gastroenterology, 2014, 12 (1) : 59 - 75
[10] Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease
Franca, Raffaella
Curci, Debora
Lucafo, Marianna
Decorti, Giuliana
Stocco, Gabriele
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (07) : 527 - 539

← 1 2 3 4 5 →